Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models

[1]  S. Aamdal,et al.  Intravenous administration of CP-4055 (ELACYT™) in patients with solid tumours. A phase I study , 2009, Acta oncologica.

[2]  C. Galmarini,et al.  CP‐4055 and CP‐4126 are active in ara‐C and gemcitabine‐resistant lymphoma cell lines , 2009, British journal of haematology.

[3]  M. Pastor-Anglada,et al.  Physiological and Pharmacological Roles of Nucleoside Transporter Proteins , 2008, Nucleosides, nucleotides & nucleic acids.

[4]  R. Wolff.  Chemotherapy for Pancreatic Cancer: From Metastatic Disease to Adjuvant Therapy , 2007, Cancer journal.

[5]  R. Shoemaker.  The NCI60 human tumour cell line anticancer drug screen , 2006, Nature Reviews Cancer.

[6]  G. Peters,et al.  Micro-Array Analysis of Resistance for Gemcitabine Results in Increased Expression of Ribonucleotide Reductase Subunits , 2006, Nucleosides, nucleotides & nucleic acids.

[7]  Franco Mosca,et al.  Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. , 2006, Cancer research.

[8]  Bauke Ylstra,et al.  In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant. , 2005, Cancer research.

[9]  E. Giovannetti,et al.  Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma , 2005, British Journal of Cancer.

[10]  J. Hoffmann,et al.  Anti‐tumor efficacy of the nucleoside analog 1‐(2‐deoxy‐2‐fluoro‐4‐thio‐β‐D‐arabinofuranosyl) cytosine (4′‐thio‐FAC) in human pancreatic and ovarian tumor xenograft models , 2005, International journal of cancer.

[11]  H. Ueno,et al.  Severe Drug Toxicity Associated with a Single-Nucleotide Polymorphism of the Cytidine Deaminase Gene in a Japanese Cancer Patient Treated with Gemcitabine plus Cisplatin , 2005, Clinical Cancer Research.

[12]  G. Peters,et al.  Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell lines. , 2004, Biochemical pharmacology.

[13]  J. Abbruzzese.  New applications of gemcitabine and future directions in the management of pancreatic cancer , 2002, Cancer.

[14]  Godefridus J Peters,et al.  Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine). , 2002, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[15]  M. Royzen,et al.  Anticancer drug delivery systems: multi-loaded N4-acyl poly(ethylene glycol) prodrugs of ara-C. II. Efficacy in ascites and solid tumors. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[16]  E. De Clercq,et al.  Antitumor activity of P-4055 (elaidic acid-cytarabine) compared to cytarabine in metastatic and s.c. human tumor xenograft models. , 1999, Cancer research.

[17]  G. Peters,et al.  Decreased resistance to gemcitabine (2',2'-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase. , 1999, Biochemical pharmacology.

[18]  C. R. Crawford,et al.  Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. , 1998, Cancer research.

[19]  A. Paterson,et al.  Sensitivity of acute leukemia cells to cytarabine is a correlate of cellular es nucleoside transporter site content measured by flow cytometry with SAENTA-fluorescein. , 1997, Blood.

[20]  D. Griffith,et al.  Nucleoside and nucleobase transport systems of mammalian cells. , 1996, Biochimica et biophysica acta.

[21]  D. Ross,et al.  Molecular effects of 2',2'-difluorodeoxycytidine (Gemcitabine) on DNA replication in intact HL-60 cells. , 1994, Biochemical pharmacology.

[22]  G. Peters,et al.  Development and molecular characterization of a 2',2'-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780. , 1994, Cancer research.

[23]  G. Peters,et al.  2',2'-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines. , 1993, Biochemical pharmacology.

[24]  H. Pinedo,et al.  Transformation of mouse fibroblasts with the oncogenes H‐ras or trk is associated with pronounced changes in drug sensitivity and metabolism , 1993, International journal of cancer.

[25]  J. Laliberté,et al.  Kinetic studies on 2',2'-difluorodeoxycytidine (Gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase. , 1993, Biochemical pharmacology.

[26]  G. Peters,et al.  Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing. , 1991, European journal of cancer.

[27]  D. Scudiero,et al.  Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. , 1991, Journal of the National Cancer Institute.

[28]  E. De Clercq,et al.  Alpha-(1-3)- and alpha-(1-6)-D-mannose-specific plant lectins are markedly inhibitory to human immunodeficiency virus and cytomegalovirus infections in vitro , 1991, Antimicrobial Agents and Chemotherapy.

[29]  D. Scudiero,et al.  New colorimetric cytotoxicity assay for anticancer-drug screening. , 1990, Journal of the National Cancer Institute.

[30]  D. Ross,et al.  Effects of 1-beta-D-arabinofuranosylcytosine on DNA replication intermediates monitored by pH-step alkaline elution. , 1990, Cancer research.

[31]  V. Heinemann,et al.  Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. , 1988, Cancer research.

[32]  Y. Lu,et al.  Biochemical and molecular properties of cisplatin-resistant A2780 cells grown in folinic acid. , 1988, The Journal of biological chemistry.

[33]  T. Chou,et al.  Kinetics and substrate specificity of human and canine cytidine deaminase. , 1986, Biochemical pharmacology.

[34]  A. Jongsma,et al.  Isolation and characterization of subclones of L1210 murine leukemia with different sensitivities to various cytotoxic agents. , 1983, Cancer research.

[35]  Lister Ta,et al.  [Treatment of acute myelogenous leukemia in adults]. , 1982, [Rinsho ketsueki] The Japanese journal of clinical hematology.

[36]  Adam P Dicker,et al.  Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. , 2009, Gastroenterology.

[37]  S. Ramalingam,et al.  Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. , 2008, The oncologist.

[38]  R. Schwendener,et al.  In vitro activity of liposomal N4octadecyl-1-β-D-arabinofurano-sylcytosine (NOAC), a new lipophilic derivative of 1-β-D-arabino-furanocylcytosine on biopsized clonogenic human tumor cells and hematopoietic precursor cells , 2004, Investigational New Drugs.

[39]  I. Fichtner,et al.  Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas. , 2004, European journal of cancer.

[40]  G. Peters,et al.  Antitumor activity of prolonged as compared with bolus administration of 2′,2′-difluorodeoxycytidine in vivo against murine colon tumors , 1996, Cancer Chemotherapy and Pharmacology.

[41]  G. Peters,et al.  Deoxycytidine kinase and deoxycytidine deaminase activities in human tumour xenografts. , 1993, European journal of cancer.

[42]  M. Lanotte,et al.  Conditions controlling long-term proliferation of Brown Norway rat promyelocytic leukemia in vitro: primary growth stimulation by microenvironment and establishment of an autonomous Brown Norway 'leukemic stem cell line'. , 1983, Leukemia research.

[43]  T. Lister,et al.  The treatment of acute myelogenous leukemia in adults. , 1982, Seminars in hematology.